In recent years, several research groups demonstrated that the levels and activity of the BACE1 protein are increased in sporadic AD patients’ brains, suggesting that BACE1 dysregulation is directly implicated in AD pathogenesis. This evidence concerns the gene BACE1 and Alzheimer disease.